comparemela.com

Latest Breaking News On - Atypical antipsychotics - Page 3 : comparemela.com

The Solution to a Common and Hazardous Symptom of BPD?

Recent research highlighted the potential role of an atypical antipsychotic to treat anxiety a prevalent and undertreated symptom in BPD that comes without the typical metabolic side effects.

United statesColorado springsNew jerseyUniversity of washingtonNew yorkRichard priceJoseph cerimeleRoger mcintyreInternational clinical psychopharmacologyWeill cornell medical collegeNeuroscience education instituteHackensack meridian school of medicineDrug administrationDivision of population healthUniversity of torontoBipolar support alliance

Schizophrenia Med Safe, Effective for Bipolar Mania

Iloperidone, an atypical antipsychotic approved for schizophrenia, appears to be safe and effective in the treatment of bipolar mania, phase 3 results of an RCT showed.

New yorkUnited statesRosarelis torresRogers mcintyreWeill cornell medical collegeVanda pharmaceuticals incUniversity of torontoDrug administrationYoung mania rating scaleClinical global impressions severityClinical global impressionMedscape medical newsRichard louis priceNew york cityBipolar disorder mania manic depression affectiveAtypical antipsychotics

Higher-Dose Atypical Antipsychotics Risky in Young Adults

Higher doses of a second-generation antipsychotic are associated with an increased risk of dying in young adults aged 18-24 years, results of a large retrospective cohort study showed.

United statesVanderbilt universityManish dubeCaleb alexanderDwayne rayAmerican psychiatric association council on childrenJohns hopkins university in baltimoreVanderbilt university school of medicineVanderbilt university schoolDrug safetyJohns hopkins universityMedscape medicalMedscape medical newsAmerican psychiatric associationNeuroleptic drugsAtypical antipsychotics

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

RISE data show UZEDY to be an effective long-acting injectable antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of.

United statesTeva pharmaceutical industries ltdTeva neuroscience incTeva pharmaceuticalsNational pregnancy registry for atypical antipsychoticsMental health services administrationTeva pharmaceutical industriesSubcutaneous extended releaseLancet psychiatryRisperidone subcutaneous extended releaseAdverse reactionsMalignant syndromeMotor impairmentNational pregnancy registryAtypical antipsychoticsHepatic impairment

UZEDY (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

02.11.2023 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release (RISE) study in The .

United statesEric hughesTeva neuroscience incMental health services administrationTeva pharmaceutical industries ltdTeva pharmaceutical industries stockNational pregnancy registry for atypical antipsychoticsExecutive vice presidentChief medical officerAfrican americanThelancet psychiatryRisperidone subcutaneous extended releaseAdverse reactionsMalignant syndromeMotor impairmentNational pregnancy registry

vimarsana © 2020. All Rights Reserved.